HYBRID EVENT: Join us in person in Tokyo, Japan or attend virtually from anywhere.
Speaker at International Conference on Clinical & Translational Oncology 2026 - Jianhua Luo
Keynote Presentation (In-Person)
Jianhua Luo, University of Pittsburgh School of Medicine, United States

Will be Updated Soon...

Speaker at International Conference on Clinical & Translational Oncology 2026 - Patricia Tai
Keynote Presentation (In-Person)
Patricia Tai, University of Saskatchewan, Canada

Objective: Merkel cell carcinoma (MCC) is a rare and aggressive form of skin cancer. Although immunotherapy has transformed MCC management, published data remain limited. This comprehensive review evaluates current evidence on immune checkpoint inhibitors (ICIs) in MCC, in relati [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Shinya Tajima
Keynote Presentation (In-Person)
Shinya Tajima, National Hospital Organization Shizuoka Medical Centre, Japan

We would like to present a only case study: However, our important findings might lead to help the interpretations of “tumour microenvironment (TME)”. We herein presenting about 70-year-old female. She presented with a palpable mass in the upper inner quadrant of t [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Sergey Suchkov
Keynote Presentation (In-Person)
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation

A new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely, personalized and precision medicine (PPM). The concept of PPM is becoming increasingly relevant for cancer treatment, moving from the ‘one-size-fits-all’ [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Isah Musa Fakai
Oral Presentation (In-Person)
Isah Musa Fakai, Abdullahi Fodio University of Science and Technology, Nigeria

The Epidermal Growth Factor Receptor (EGFR) pathway is an important signaling cascade currently investigated for its involvement in cancer therapy. In this study, chalepin isolated from Ruta angustifolia was evaluated for its down regulatory activity on the EGFR signaling cascade [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Patricia Tai
Oral Presentation (In-Person)
Patricia Tai, University of Saskatchewan, Canada

Background: Recurrent prostate cancer is detected by a rising prostate-specific antigen (PSA) level. Recent advances in prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) have improved restaging and subsequent management. Objective: To summarize recen [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Sergey Suchkov
Oral Presentation (In-Person)
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation

A new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely, personalized and precision medicine (PPM). In this sense, Personalized & Precision Oncology (PPO) is an innovative approach to cancer management and is oriented t [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Maria Isabel Sollozo Dupont
Oral Presentation (In-Person)
Maria Isabel Sollozo Dupont, National Institute of Perinatology Isidro Espinosa de los Reyes, Mexico

Breast cancer is a major public health issue since it is the most common cause of death from malignant neoplasms in women over 25 around the world, especially in low-income countries where death rates are higher. In Mexico, preventative efforts are made harder by the fact that sc [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Paulraj S
Oral Presentation (In-Person)
Paulraj S, Chennai Snake Park Trust, India

The origin, growth and spread of various cancers follow some common regulatory paths. Although hundreds of genes are involved in this process, most of these paths are initiated and controlled by one dominant and central factor, the Hypoxia Inducible Factor 1α (HIF-1α) [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Anbuganapathi G
Oral Presentation (In-Person)
Anbuganapathi G, Anbu Hospital, India

In the Indian context, the Siddha system of medicine (one of the oldest traditional systems, primarily from South India) is increasingly utilized as a powerful complementary and alternative medicine (CAM) for cancer. This is one of the approved medical systems under the Ministry [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Ramalingam K
Oral Presentation (In-Person)
Ramalingam K, Mediclone Biotech Research Centre, India

This study aims to investigate the profound interplay between lifestyle, environmental factors, and the psychological burden of a cancer diagnosis. While medical advancements have improved survival rates, the diagnosis frequently triggers a severe "fear psychosis," char [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - K R Muralidhar
Oral Presentation (In-Person)
K R Muralidhar, Karkinos Healthcare Private Limited, India

Introduction and Objective: Radiation therapy plays a central role in cancer management; however, its success is often limited by tumour radio resistance and the risk of late treatment-related toxicities, even with advanced technologies and across various forms of radiation and i [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Vaibhav Roy
Oral Presentation (In-Person)
Vaibhav Roy, Sharda University, India

Background: Immune checkpoint inhibitors (ICIs) significantly improve cancer outcomes but can cause rare, potentially fatal cardiotoxicity, including myocarditis and major adverse cardiovascular events (MACE). Machine learning (ML) and artificial intelligence (AI) models hav [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Nermeen Mohamed Elbakary
Oral Presentation (In-Person)
Nermeen Mohamed Elbakary, Egyptian Atomic Energy Authority, Egypt

Tumor resistance is typically blamed for the failure of radiotherapy and chemotherapy to treat cancer in clinic patients. To improve the cytotoxicity of tumor cells using radiation in conjunction with specific tumor-selective cytotoxic drugs is crucial. Pomegranate has received o [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Mercy Osoro
Oral Presentation (In-Person)
Mercy Osoro, National Cancer Institute of Kenya, Kenya

Background: With rising cancer incidence and expanding access to treatment, the population of cancer survivors is increasing. However, survivorship and long-term care remain fragmented, with many patients lacking structured follow-up, psychosocial support, and management of late [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Jinhua Wang
Oral Presentation (In-Person)
Jinhua Wang, The Affiliated Cancer Hospital of Nanjing Medical University, China

Adult-type ovarian Granulosa Cell Tumor (AGCT) is a rare low-grade malignant sex cord-stromal tumor, accounting for 2–5% of all ovarian malignancies, with 95% of cases occurring in middle-aged women aged 45–55 years. Cases in young patients ≤25 years old are extrem [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Zhi Gang Sun
Oral Presentation (In-Person)
Zhi Gang Sun, China Japan Friendship Hospital, China

Background: The 9th edition American Joint Committee on Cancer (AJCC) staging system has been proposed by the AJCC Cancer Expert Panel (AJCCCCEP). The prognostic discriminatory validity of the new staging system in actual patient cohorts has not been fully validated. Aim: [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Yunjian Zhang
Oral Presentation (In-Person)
Yunjian Zhang, Sun Yat-Sen University First Affiliated Hospital, China

Background: Over the past decade, Robotic and laparoscopic techniques in nipple-sparing mastectomy (NSM), have gained prominence in the field of breast surgery. However, the complexity of these procedures necessitates systematic training programs to ensure surgical competency. Th [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Amanuel Tadelle Fekadu
Oral Presentation (In-Person)
Amanuel Tadelle Fekadu, University of Gondar, Ethiopia

Background: Chemotherapy-induced neutropenia is a frequent and potentially life-threatening complication that may lead to treatment delay, dose reduction, infection, and poor cancer outcomes. Evidence on the incidence and predictors of neutropenia among cancer patients in Ethiopi [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Hailu Aragie Chekol
Oral Presentation (In-Person)
Hailu Aragie Chekol, University of Gondar, Ethiopia

Background: Cancer is a leading cause of morbidity in Ethiopia, where a growing burden of disease meets limited healthcare infrastructure. While clinical management is prioritized, the psychosocial dimensions of the patient experience remain under-explored. This systematic qualit [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Ahora Chehri
Poster Presentation (In-Person)
Ahora Chehri, Valencian Institute of Oncology and Medico Cancer Center, Germany

Purpose of the study: This study aims to analyze global research trends and emerging themes in the application of stem cell biology for cancer therapy. The intent is to map the intellectual landscape and identify key areas of focus and collaboration from 2020 to 2024.  Me [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Mengsen Li
Poster Presentation (In-Person)
Mengsen Li, Hainan Medical University, China

Lung cancer is one of the most common malignancies worldwide, and due to its high mortality rate and resistance to treatment, there is an urgent need to develop effective treatments with low toxicity. Long Stephania Herb(LSH) is a tropical herb used clinically for the treatment o [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Rajvir Dahiya
Keynote Presentation (Virtual)
Rajvir Dahiya, University of California San Francisco, United States

Current screening methods—radiological imaging, DNA-based tests, and pathological assessments—often fail to detect malignancies at early stages. Despite technological advances, gene-based diagnostics specifically designed for early cancer detection remain limited. To [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Yan Leyfman
Keynote Presentation (Virtual)
Yan Leyfman, NYP- Meyer Cancer Center, United States

Background: Large language models (LLMs) are increasingly used in oncology clinical workflows; however, real-world clinician adoption has outpaced formal institutional guidance and systematic safety validation. Existing evaluations often rely on aggregate performance metrics, whi [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Jose Manuel Cervera Grau
Keynote Presentation (Virtual)
Jose Manuel Cervera Grau, Preclinical Lab and Computational Drug Discovery Program, Relayer Biotech Inc, Spain

Will be Updated Soon...

Speaker at International Conference on Clinical & Translational Oncology 2026 - George Zachos
Keynote Presentation (Virtual)
George Zachos, University of Crete, Greece

Chromatin bridges are strings of mis-segregated chromatin connecting the anaphase poles or daughter nuclei in mitotic cell division and can arise from incomplete DNA replication or decatenation, or from dicentric chromosomes generated by end-to-end chromosome fusions. Chromatin b [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Paulo Cesar De Morais
Keynote Presentation (Virtual)
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil

In this keynote lecture, exotic nanomagnetic materials (magnetic nanorings - MNRs) will be introduced as a very promising material for application in magnetic hyperthermia (MHT), an advanced cancer therapeutic modality. The chemical synthesis and the characterization of the [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Nayara Delgado Andre
Oral Presentation (Virtual)
Nayara Delgado Andre, Federal University of São João del-Rei (UFSJ), Brazil

Aberrant glycosylation is a defining feature of cancer and extends beyond tumour cells to tumour-derived extracellular vesicles (TDEVs), which are increasingly recognised as key mediators of intercellular communication within the tumour microenvironment. However, the contribution [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Eleni Petsalaki
Oral Presentation (Virtual)
Eleni Petsalaki, University of Crete, Greece

Chromatin bridges are strands of incompletely segregated DNA connecting the anaphase poles or daughter nuclei. Chromatin bridges can arise from incompletely replicated DNA, defective resolution of DNA catenates or dicentric chromosomes which are formed by chromosome fusions. If u [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Omar Mohammad Alqaisi
Oral Presentation (Virtual)
Omar Mohammad Alqaisi, Al-Zaytoonah University, Jordan

Selenium deficiency is associated with impaired immunity and leukemogenesis. Selenium compounds exhibit antiproliferative and proapoptotic effects in leukemic models, indicating therapeutic potential. However, no comprehensive review has assessed selenium’s impact on leukem [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Omar Mohammad Alqaisi
Oral Presentation (Virtual)
Omar Mohammad Alqaisi, Al-Zaytoonah University, Jordan

Sexual health is a fundamental component of quality of life that is frequently compromised in cancer patients. In melanoma care, these issues remain under addressed despite increasing survivorship. This scoping review aimed to map the current literature on sexual health concerns [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Ratan Kumar Sarkar
Oral Presentation (Virtual)
Ratan Kumar Sarkar, Independent Researcher, India

The cancer drugs(SBDD) generally blocks cell signaling but it also blocks disintegration of lunar gravity(705) and electronic time(27 or 27*0.0019 = 0.0513 or 513) that would not co-exists driving to protein synthesis until neutralization of 27 e.g. 609(AFP) + 291 = 900 where 609 [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Saumya Pandey
Oral Presentation (Virtual)
Saumya Pandey, Indira IVF Hospital, India

Objectives: Inflammation is a hallmark of HPV-mediated cervical cancer; Matrix metalloproteinase [MMP]-2 and tissue inhibitor of metalloproteinase [TIMP]-2 are emerging as pivotal players in inflammation and carcinogenesis. My study aimed to evaluate the role of MMP-2 (-735C>T [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Arthi Roy
Oral Presentation (Virtual)
Arthi Roy, Pabna Medical College, Bangladesh

Background: Breast cancer remains the most commonly diagnosed malignancy and a leading cause of cancer-related mortality among women worldwide. Despite advances in diagnosis and treatment, its global burden continues to rise, highlighting the need for modifiable prognostic factor [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Arthi Roy
Oral Presentation (Virtual)
Arthi Roy, Pabna Medical College, Bangladesh

Background: Colorectal carcinoma (CRC) remains a leading cause of cancer-related morbidity and mortality worldwide. Emerging evidence suggests that vitamin D, beyond its classical role in bone metabolism, may influence carcinogenesis through its effects on cell proliferation [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Yi Chih Liang
Poster Presentation (Virtual)
Yi Chih Liang, National Sun Yat-Sen University, Taiwan

Background: Upper tract urothelial carcinoma (UTUC) is a distinct malignancy arising from the renal pelvis or ureter. Globally, UTUC represents 5–10% of urothelial carcinomas, but in Taiwan its incidence reaches up to 30%, the highest reported worldwide. This epidemiologica [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Wu Junyao
Poster Presentation (Virtual)
Wu Junyao, Changhai Hospital, China

Objective: The Artificial Intelligence (AI) - assisted detection reduces underdiagnosed or overlooked early esophageal cancers. We performed a meta-analysis to determine the diagnostic accuracy of AI used in white light endoscopy of patients with early esophageal cancer. [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Widia Rosita
Poster Presentation (Virtual)
Widia Rosita, Dr. Sardjito General Hospital, Indonesia

Sinonasal squamous cell carcinoma (SNSCC) is a rare head and neck malignancy that often presents at an advanced stage because initial symptoms mimic benign inflammatory disease. In high tuberculosis (TB) burden countries such as Indonesia, therapeutic decision-making may be furth [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Can Küçük
Oral Presentation (Virtual)
Can Küçük, Dokuz Eylül University, Turkey

Multiple myeloma (MM) is a relatively frequent type of hematological malignancy that consists of proliferation of abnormal plasma cells in the bone marrow. MGUS and SMM are asymptomatic precursor conditions that can potentially transition to multiple myeloma. Previous reports ind [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Bing Shen
Oral Presentation (Virtual)
Bing Shen, Tongji University, China

Bladder cancer is one of the most common malignancies worldwide, and early diagnosis and regular follow-up are crucial for improving patient prognosis. Cystoscopy and tissue biopsy, the gold standards for diagnosing bladder cancer, are invasive and may result in complications. Ur [....] » Read More

Speaker at International Conference on Clinical & Translational Oncology 2026 - Delphine Delacour
Oral Presentation (Virtual)
Delphine Delacour, CNRS, France

Intestinal cancers are among the most prevalent epithelial malignancies and constitute a major clinical burden, largely due to late diagnosis and difficulty of predicting disease progression. Tumorigenesis mainly initiates within intestinal crypts, which harbor stem cell (SC) and [....] » Read More

Youtube
Watsapp